[Medical management of chronic rhinosinusitis with macrolides].
Long-term, low-dose macrolide therapy is effective in the treatment of chronic airway inflammation. It is believed that macrolide antibiotics produce this benefit through an antiinflammatory effect that is separate from their antibiotic effect. Eosinophils are key mediators in the inflammation seen in chronic rhinosinusitis. The effect of macrolides on eosinophilic inflammation is presented. In vitro studies recently have suggested that macrolides increase eosinophil apoptosis and reduce production of eosinophil chemotactic cytokines and adhesion molecules. In vivo studies have shown a reduction in eosinophil count and activity in asthma and chronic rhinosinusitis. Further in vitro and clinical studies are required to investigate this subject. The authors present preliminary results of clinical trial.
Górski
Norbert P
NP
Katedra i Klinika Otolaryngologii Akademii Medycznej, Warszawie. ngorski@amwaw.edu.pl
Krzeski
Antoni
A
D017209:Apoptosis / Q000187:drug effects; D015815:Cell Adhesion Molecules / Q000187:drug effects; D018925:Chemokines / Q000378:metabolism; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D004804:Eosinophils / Q000187:drug effects* / Q000378:metabolism; D006801:Humans; D066298:In Vitro Techniques; D018942:Macrolides / Q000627:therapeutic use*; D012221:Rhinitis, Allergic, Perennial / Q000188:drug therapy* / Q000503:physiopathology; D012852:Sinusitis / Q000188:drug therapy* / Q000503:physiopathology; D016896:Treatment Outcome
D015815:Cell Adhesion Molecules; D018925:Chemokines; D018942:Macrolides